Acessibilidade / Reportar erro

Exfoliation syndrome associated with LOXL1 gene polymorphisms in a Black patient from Latin America: a case report

Síndrome de esfoliação associada a polimorfismos do gene LOXL1 em paciente negro da América Latina: relato de caso

ABSTRACT

A 89-year-old Black female with a 6-year history of advanced open-angle glaucoma was referred to the Glaucoma Service of the Ophthalmology Department - Federal University of São Paulo (UNIFESP). Best-corrected visual acuity was 20/400 in the right eye and 20/60 in the left eye. Pseudoexfoliation material was observed at the iris border, angle, and the anterior lens surface. Anterior biomicroscopy revealed exfoliation material forming an evident peripheral zone and a central disc separated by a clear intermediate zone on the anterior lens surface OU. Gonioscopy showed an open-angle Sampaolesis’s line and whitish material deposits OU. Fundus examination revealed a cup-to-disc ratio of 1.0 OU with peripapillary atrophy. Genetic analysis for single nucleo­tide polymorphisms of the lysyl oxidase-like 1 gene linked to exfoliation syndrome identified two such single nucleotide polymorphisms, rs1048661 and rs216524.

Keywords:
Exfoliation syndrome; African continental ancestry group; Exfoliation syndrome; Lysyl oxidase-like 1 gene; Brazil

RESUMO

Uma mulher negra de 89 anos com um histórico de seis anos de glaucoma avançado de ângulo aberto avançado foi encaminhada ao Serviço de Glaucoma do Departamento de Oftalmologia da Universidade Federal de São Paulo (UNIFESP). A acuidade visual melhor corrigida era 20/400 no olho direito e 20/60 no olho esquerdo. Material pseudo-exfoliativo foi observado na borda iriana, ângulo e superfície anterior do cristalino. A biomicroscopia de segmento anterior demonstrou material exfoliativo formando uma zona periférica evidente e um disco central separado por uma zona intermediária livre na cápsula anterior do cristalino. A gonioscopia mostrou uma linha de Sampaolesi de ângulo aberto e depósitos esbranquiçados. O exame de fundo de olho revelou disco óptico com escavação total em ambos os olhos com atrofia peripapilar. A análise genética para polimorfismos de nucleotídeo único do gene semelhante à lysyl oxidase-like 1 ligado à síndrome de esfoliação identificou dois desses polimorfismos de nucleotídeo único, rs1048661 e rs216524.

Descritores:
Síndrome de exfoliação; Grupo com ancestrais do continente africano; Síndrome de exfoliação; Gene LOXL-1; Brasil

INTRODUCTION

Exfoliation syndrome (XFS) is the most identifiable cause of open-angle glaucoma(11 Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45(4):265-315.) and its prevalence has been studied in many different countries around the world. However, there are no large population studies on XFS incidence or etiology in South America.

The syndrome is often regarded as predominant in Caucasians due to high prevalence in Scandinavia(22 Ringvold A. Epidemiology of glaucoma in northern Europe [PMID: 8744847]. Eur J Ophthalmol. 1996;6(1):26-9.). There is strong evidence for a genetic predisposition to XFS based on associations with three single nucleo­tide polymorphisms (SNPs) of the lysyl oxidase-like 1 (LOXL-1) gene (15q24)(33 Álvarez L, García M, González-Iglesias H, Escribano J, Rodríguez-Calvo PP, Fernández-Vega L, et al. LOXL1 gene variants and their association with pseudoexfoliation glaucoma (XFG) in Spanish patients. BMC Med Genet. 2015;16(1):72.): rs1048661 (c.422G>T; p.Arg141Leu), rs3825942 (c.458G>A; p.Gly153Asp), and rs2165241 (c.1102 + 1976T>C). The LOXL-1 enzyme promotes cross-linking of collagen and elastin in the extracellular matrix, but its exact role in XFS pathogenesis has not been established.

While strongly linked to Caucasian ancestry, recent studies have demonstrated XFS in Black populations, such as South Africans(44 Rotchford AP, Kirwan JF, Johnson GJ, Roux P. Exfoliation syndrome in black South Africans. Arch Ophthalmol. 2003;121(6):863-70.). Exfoliative syndrome and resulting exfoliative glaucoma (XFG) diagnosis may be under-diagnosed in the Black population because of low suspicion. This report describes the case of a 89-year-old Black female with advanced glaucoma, clear signs of pseudoexfoliative material, and XFS-linked SNPs of LOXL-1, thus confirming the presence of XFS in the South American Black population.

CASE REPORT

A 89-year-old Black female patient was admitted with a 6-year history of advanced open-angle glaucoma with progressive vision loss OU. She also had a history of trabeculectomy OS 2 years before her first consultation at our service. Best-corrected visual acuity was 20/400 OD and 20/60 OS. Intraocular pressure (IOP) was 16 OU (4 p.m.) under topical therapy (Timolol maleate 0.5% BID, Brimonidine tartrate 0.2% BID, and Travaprost 0.004% QD).

Anterior biomicroscopy revealed pseudoexfoliative material forming three zones on the anterior lens capsule OU (Figure 1). The patient also had 2+ nuclear ca­taracts OU. Gonioscopy revealed an open-angle Sam­paolesis’s line and whitish material deposits (Figure 2) OU. Fundus examination showed a cup-to-disc ratio of 1.0 OU with peripapillary atrophy (Figure 3). Left eye achromatic automated perimetry demonstrated advanced visual field damage.

Figure 1
Pseudoexfoliative material in the lens capsule of the right eye. The relatively homogeneous central disk and peripheral zone are separated by a clear intermediate zone.

Figure 2
Gonioscopy of the right eye showing pseudoexfoliative material and Sampaolesi’s line.

Figure 3
Fundoscopy showing a 1.0 cup-to-disk ratio and peripapillary atrophy OU.

Given these typical findings of XFS, genetic molecular testing was conducted to evaluate the presence of three LOXL-1 SNPs linked to XFS. The test revealed the presence of rs1048661 and rs216524 in heterozygosis and absence of rs3825942 (Figure 4).

Figure 4
LOXL1 gene sequencing for the polymorphisms (from top to the bottom) rs1048661 (present), rs3825942 (absent), and rs2165241 (present).

DISCUSSION

Exfoliation syndrome is a frequent cause of open-angle glaucoma, and has important implications for clinical management as XFS is associated with more severe glaucoma progression(55 Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013;120(3):512-9.). Here we demonstrate the occurrence of XFS linked to LOXL-1 SNPs in a Black patient from South America, suggesting under-reported prevalence in this population.

Exfoliation syndrome is characterized by deposition of fibrilar material on the anterior segment of the eye, most prominently at the pupillary margin and the anterior lens capsule. Deposits at the trabecular meshwork may promote IOP elevation and glaucoma. Exfoliation syndrome is also accompanied by zonular weakness and poor dilatation with concomitant phacodonesis and iridodonesis. These conditions predispose individuals with XFS to complications such as zonular instability and vitreous loss during and after cataract surgery(66 Shingleton BJ, Crandall AS, Ahmed II. Pseudoexfoliation and the cataract surgeon: preoperative, intraoperative, and postoperative issues related to intraocular pressure, cataract, and intraocular lenses. J Cataract Refract Surg. 2009;35(6):1101-20. Review.). In light of these risks, there are intensive efforts to understand the pathomechanisms of XFS in detail, and such studies have identified strong associations with SNPs of LOXL-1 (rs1048661, rs3825942, and rs2165241). However, the presence of these polymorphisms is not the only determinant of XFS expression. Prevalence varies widely among populations and it is known that the same allele that confers higher risk in one population can be protective in another. Environmental and behavioral factors also appear important for the genesis of XFS(77 Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol. 2003;136(1):41-6.

8 Ritch R. Ocular and systemic manifestations of exfoliation syndrome [PubMed]. J Glaucoma. 2014;23(8 Suppl 1):S1-8.
-99 Kang JH, Wiggs JL, Pasquale LR. Relation between time spent outdoors and exfoliation glaucoma or exfoliation glaucoma suspect. Am J Ophthalmol. 2014;158(3):605-14.e1.), such as higher altitude, caffeine consumption, low folate, and excessive sun exposure (i.e., outdoor activities and more numerous sunny days and longer daylight hours)(99 Kang JH, Wiggs JL, Pasquale LR. Relation between time spent outdoors and exfoliation glaucoma or exfoliation glaucoma suspect. Am J Ophthalmol. 2014;158(3):605-14.e1.-1010 Nathan N, Kuchtey RW. Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma. Curr Ophthalmol Rep. 2016;4(4):206-12.).

Exfoliation material may be found in different visceral organs of patients with XFS(88 Ritch R. Ocular and systemic manifestations of exfoliation syndrome [PubMed]. J Glaucoma. 2014;23(8 Suppl 1):S1-8.), and XFS has been associated with cardiovascular and cerebrovascular diseases, elevated homocysteine levels(77 Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol. 2003;136(1):41-6.), and deafness(88 Ritch R. Ocular and systemic manifestations of exfoliation syndrome [PubMed]. J Glaucoma. 2014;23(8 Suppl 1):S1-8.). Therefore, early diagnosis and management of both ocular and systemic conditions is critical. This makes the XFS a very complex disease associated with genetic and environmental factors contributing to the disease appearance and severity.

The current case patient was positive for two of the three SNPs previously linked to XFS, rs1048661 and rs216524 (Figure 4). She also presented with the typical findings of XFS. While originally described in Scandinavians, XFS and XFG have worldwide distribution, and recent studies have revealed considerable prevalence among Blacks. To our knowledge, however, this is the first case described in a Black patient from South America.

Diagnosis of XFS relies on careful examination and a high level of clinical suspicion. The possibility of XFS should be considered when examining older patients with glaucoma regardless of ethnicity.

  • Funding: No specific financial support was available for this study.

REFERENCES

  • 1
    Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45(4):265-315.
  • 2
    Ringvold A. Epidemiology of glaucoma in northern Europe [PMID: 8744847]. Eur J Ophthalmol. 1996;6(1):26-9.
  • 3
    Álvarez L, García M, González-Iglesias H, Escribano J, Rodríguez-Calvo PP, Fernández-Vega L, et al. LOXL1 gene variants and their association with pseudoexfoliation glaucoma (XFG) in Spanish patients. BMC Med Genet. 2015;16(1):72.
  • 4
    Rotchford AP, Kirwan JF, Johnson GJ, Roux P. Exfoliation syndrome in black South Africans. Arch Ophthalmol. 2003;121(6):863-70.
  • 5
    Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013;120(3):512-9.
  • 6
    Shingleton BJ, Crandall AS, Ahmed II. Pseudoexfoliation and the cataract surgeon: preoperative, intraoperative, and postoperative issues related to intraocular pressure, cataract, and intraocular lenses. J Cataract Refract Surg. 2009;35(6):1101-20. Review.
  • 7
    Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol. 2003;136(1):41-6.
  • 8
    Ritch R. Ocular and systemic manifestations of exfoliation syndrome [PubMed]. J Glaucoma. 2014;23(8 Suppl 1):S1-8.
  • 9
    Kang JH, Wiggs JL, Pasquale LR. Relation between time spent outdoors and exfoliation glaucoma or exfoliation glaucoma suspect. Am J Ophthalmol. 2014;158(3):605-14.e1.
  • 10
    Nathan N, Kuchtey RW. Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma. Curr Ophthalmol Rep. 2016;4(4):206-12.

Publication Dates

  • Publication in this collection
    Sep-Oct 2018

History

  • Received
    13 Apr 2018
  • Accepted
    27 May 2018
Conselho Brasileiro de Oftalmologia Rua Casa do Ator, 1117 - cj.21, 04546-004 São Paulo SP Brazil, Tel: 55 11 - 3266-4000, Fax: 55 11- 3171-0953 - São Paulo - SP - Brazil
E-mail: abo@cbo.com.br